Market Access News | pharmaphorum

News

Vydura is first NICE-backed oral GPCR for acute migraine

Pfizer's Vydura has become the first drug in the oral GPCR receptor antagonist class to be recommended for routine NHS use as a treatment for acute migraine.

News

Oral phenylephrine vote may see OTC products pulled in US

An FDA advisory committee has concluded that a commonly used decongestant ingredient used in cold and allergy products does not have any efficacy, raising the possibility

News

EU clears review of Xtandi in earlier-stage prostate cancer

The EMA will kick off a review of Astellas and Pfizer's prostate cancer therapy Xtandi in an earlier-stage form of the cancer, which if approved could give the product a l

News

FDA clears new Pfizer, Moderna COVID jabs as cases tick up

The FDA has authorised updated versions of Pfizer/BioNTech and Moderna's mRNA-based COVID-19 vaccines targeting the XBB.1.5 subvariant, in time for the start of a new autu

News

NICE changes its mind on Lilly's Mounjaro for diabetes

Around 180,000 people with type 2 diabetes in the UK could be in line for treatment with Eli Lilly's Mounjaro after the drug was recommended for NHS use by cost-effectiven

News

FDA blocks new use for AstraZeneca's Ultomiris

AstraZeneca has been successful at rolling out its long-acting complement C5 inhibitor Ultomiris in the uses approved for its predecessor Soliris – until now, that is.

Vydura is first NICE-backed oral GPCR for acute migraine

Oral phenylephrine vote may see OTC products pulled in US

EU clears review of Xtandi in earlier-stage prostate cancer

FDA clears new Pfizer, Moderna COVID jabs as cases tick up

NICE changes its mind on Lilly's Mounjaro for diabetes

FDA blocks new use for AstraZeneca's Ultomiris

Bankruptcy threat looms as Quince runs out of options

How to meet your physicians where they are online

News

Editor's Picks